Front Matter
Show Items
Solution/Suspension/Syrup
Show Items
Topical/Ophthalmic Solution
Show Items
Commercially Available Products (Use Only if Commercially Unavailable)
Acetaminophen Suspension 50 mg/mL
Alprazolam Suspension 1 mg/mL—Formulation 1
Alprazolam Suspension 1 mg/mL—Formulation 2
Amlodipine Besylate Suspension 1 mg/mL—Formulation 1
Amlodipine Besylate Suspension 1 mg/mL—Formulation 2
Aprepitant Suspension 20 mg/mL
Aripiprazole Suspension 1 mg/mL
Baclofen Suspension 2 mg/mL
Baclofen Suspension 10 mg/mL—Formulation 1
Baclofen Suspension 10 mg/mL—Formulation 2
Baclofen Syrup 5 mg/mL*
Caffeine Citrate Solution 20 mg/mL
Carbamazepine Suspension 25 mg/mL
Carbamazepine Syrup 40 mg/mL
Cholecalciferol Suspension 50,000 units/mL
Ciprofloxacin Hydrochloride Suspension 50 mg/mL—Formulation 1
Ciprofloxacin Hydrochloride Suspension 50 mg/mL—Formulation 2
Cyclosporine Suspension 100 mg/mL
Dexamethasone Suspension 1 mg/mL
Diazoxide Suspension 10 mg/mL—Formulation 1
Diazoxide Suspension 10 mg/mL—Formulation 2
Enalapril Maleate Suspension 0.1 mg/mL
Enalapril Maleate Suspension 1 mg/mL—Formulation 1
Enalapril Maleate Suspension 1 mg/mL—Formulation 2
Enalapril Maleate Suspension 1 mg/mL—Formulation 3
Famotidine Suspension 8 mg/mL
Famotidine Syrup 8 mg/mL
Fluoxetine Hydrochloride Syrup 1 mg/mL
Fluoxetine Hydrochloride Syrup 2 mg/mL
Furosemide Suspension 2 mg/mL
Furosemide Suspension 9.6 mg/mL
Gabapentin Suspension 50 mg/mL
Gabapentin Suspension 100 mg/mL—Formulation 1
Gabapentin Suspension 100 mg/mL—Formulation 2
Glycopyrrolate Suspension 0.2 mg/mL
Glycopyrrolate Suspension 0.5 mg/mL—Formulation 1
Glycopyrrolate Suspension 0.5 mg/mL—Formulation 2
Haloperidol Suspension 0.5 mg/mL
Indomethacin Syrup 2 mg/mL
Isoniazid Suspension 10 mg/mL
Itraconazole Suspension 20 mg/mL—Formulation 1
Itraconazole Suspension 20 mg/mL—Formulation 2
Itraconazole Syrup 40 mg/mL
Levodopa 5 mg/mL and Carbidopa 1.25 mg/mL Suspension—Formulation 1
Levodopa 5 mg/mL and Carbidopa 1.25 mg/mL Suspension—Formulation 2
Levofloxacin Suspension 50 mg/mL—Formulation 1
Levofloxacin Suspension 50 mg/mL—Formulation 2
Levothyroxine Sodium Solution 25 mcg/mL
Lisinopril Suspension 1 mg/mL—Formulation 1
Lisinopril Suspension 1 mg/mL—Formulation 2
Lisinopril Syrup 1 mg/mL
Lisinopril Syrup 2 mg/mL
Lorazepam Suspension 1 mg/mL
Mercaptopurine Suspension 10 mg/mL
Mercaptopurine Syrup 50 mg/mL
Methadone Hydrochloride Suspension 10 mg/mL
Methotrexate Syrup 2 mg/mL
Midazolam Hydrochloride Gelatin 1 mg/mL
Midazolam Hydrochloride Gelatin 2 mg/mL
Midazolam Hydrochloride Suspension 1 mg/mL
Midazolam Hydrochloride Syrup 2.5 mg/mL
Morphine Hydrochloride Solution 1 mg/mL
Morphine Sulfate Solution 0.4 mg/mL*
Mycophenolate Mofetil Suspension 50 mg/mL
Mycophenolate Mofetil Syrup 100 mg/mL
Naproxen Suspension 25 mg/mL
Nitrofurantoin Suspension 2 mg/mL
Nizatidine Solution 2.5 mg/mL
Ondansetron Hydrochloride Suspension 0.8 mg/mL—Formulation 1
Ondansetron Hydrochloride Suspension 0.8 mg/mL—Formulation 2
Oseltamivir Phosphate Suspension 6 mg/mL
Oseltamivir Phosphate Syrup 6 mg/mL
Oseltamivir Phosphate Syrup 15 mg/mL
Phenobarbital Suspension 9 mg/mL
Phenobarbital Suspension 9.3 mg/mL
Phenobarbital Suspension 10 mg/mL
Phenobarbital Suspension 15 mg/mL
Phenytoin Suspension 15 mg/mL
Potassium Chloride Syrup 1 mEq/mL
Prednisolone Disodium Phosphate Solution 10 mg/mL
Prednisolone Sodium Phosphate Suspension 1.4 mg/mL
Prednisone Syrup 0.5 mg/mL
Pregabalin Suspension 20 mg/mL
Propranolol Hydrochloride Suspension 0.5 mg/mL
Propranolol Hydrochloride Suspension 1 mg/mL
Propranolol Hydrochloride Suspension 5 mg/mL
Rufinamide Suspension 40 mg/mL
Sertraline Hydrochloride Suspension 10 mg/mL
Sildenafil Citrate Suspension 2.5 mg/mL
Simvastatin Suspension 1 mg/mL
Sotalol Hydrochloride Suspension 5 mg/mL
Spironolactone Suspension 2 mg/mL
Spironolactone Suspension 2.5 mg/mL
Spironolactone Suspension 25 mg/mL—Formulation 1
Spironolactone Suspension 25 mg/mL—Formulation 2
Spironolactone Suspension 26 mg/mL
Spironolactone Syrup 2.5 mg/mL
Spironolactone Syrup 5 mg/mL*
Spironolactone Syrup 10 mg/mL
Theophylline Suspension 5 mg/mL—Formulation 1
Theophylline Suspension 5 mg/mL—Formulation 2
Trimethoprim Suspension 10 mg/mL—Formulation 1
Trimethoprim Suspension 10 mg/mL—Formulation 2
Valganciclovir Hydrochloride Suspension 30 mg/mL
Valganciclovir Hydrochloride Suspension 60 mg/mL
Vancomycin Hydrochloride Suspension 25 mg/mL
Vancomycin Hydrochloride Syrup 25 mg/mL
Voriconazole Suspension 40 mg/mL
Zidovudine Syrup 10 mg/mL
Back Matter
Show Items
  • 1.

    General Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations. In: United States Pharmacopeia and National Formulary (USP 43-NF 38). Revised January 1, 2014. Rockville, MD: The United States Pharmacopeia Convention Inc; 2020.

  • 1.

    Proposed Revisions to <795> Pharmaceutical Compounding – Nonsterile Preparations. The United States Pharmacopeia Convention Inc; 2021. Available at: https://go.usp.org/l/323321/2021-08-31/5kmcjf/323321/1630438802OI493yjz/BUD_Scientific_Rationale_for_the_2021_Proposed_Revisions_to__795_.docx. Accessed November 15, 2021.

  • 1.

    Pancorbo SA, Campagna KD, Devenport JK, et al.Task force report of competency statements for pharmacy practice. Am J Pharm Educ. 1987; 51:196–206.

    • Search Google Scholar
    • Export Citation
  • 2.

    Allen LV Jr. Establishing and marketing your extemporaneous compounding service. US Pharm. 1990; 15(Dec):74–7.

  • 3.

    Remington's pharmaceutical sciences. 18th ed. Gennaro AR, ed. Easton, PA: Mack Publishing; 1990; 1630–1, 1658, 1660.

  • 4.

    The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th ed. Rockville, MD: The United States Pharmacopeial Convention; 1989.

    • Search Google Scholar
    • Export Citation
  • 5.

    USP DI Volume III: Approved drug products and legal requirements. 14th ed. Rockville, MD: The United States Pharmacopeial Convention; 1994.

    • Search Google Scholar
    • Export Citation
  • 6.

    USP DI Volume I: Drug information for the health care professional. 14th ed. Rockville, MD: The United States Pharmacopeial Convention; 1994.

    • Search Google Scholar
    • Export Citation
  • 7.

    29 §C.F.R. 1910. 1200(1990).

  • 8.

    ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033–49.

  • 9.

    Feinberg JL. Complying with OSHA's Hazard Communication Standard. Consult Pharm. 1991; 6:444, 446, 448.

  • 10.

    Myers CE. Applicability of OSHA Hazard Communication Standard to drug products. Am J Hosp Pharm. 1990; 47:1960–1.

  • 11.

    21 C.F.R. §211.137.

  • 12.

    Connors KA, Amidon GL, Stella VJ. Chemical stability of pharmaceuticals: a handbook for pharmacists. 2nd ed. New York: Wiley; 1986.

  • 13.

    American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993; 50:305–14.

    • Search Google Scholar
    • Export Citation
  • 14.

    Fitzgerald WL Jr. The legal authority to compound in pharmacy practice. Tenn Pharm. 1990; 26(Mar):21–2.

  • 1.

    Associated Press. Pittsburgh woman loses eye to tainted drugs; 12 hurt. Baltimore Sun. 1990; Nov 9:3A.

  • 2.

    Associated Press. Eye drop injuries prompt an FDA warning. N Y Times. 1990; 140(Dec 9):39I.

  • 3.

    Jeglum EL, Rosenberg SB, Benson WE. Preparation of intravitreal drug doses. Ophthalmic Surg. 1981; 12:355–9.

  • 4.

    Reynolds LA. Guidelines for preparation of sterile ophthalmic products. Am J Hosp Pharm. 1991; 48:2438–9.

  • 5.

    Reynolds LA, Closson R. Ophthalmic drug formulations. A handbook of extemporaneous products. Vancouver, WA: Applied Therapeutics; 1993.

  • 6.

    The United States Pharmacopeia, 22nd rev., and The National Formulary, 17th ed. Rockville, MD: The United States Pharmacopeial Convention; 1989:1692–3.

  • 7.

    Allen LV. Indomethacin 1% ophthalmic suspension. US Pharm. 1991; 16(May):82–3.

  • 8.

    American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033–49.

    • Search Google Scholar
    • Export Citation
  • 9.

    OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm. 1986; 43:1193–204.

  • 10.

    Ansel HC, Popovich NG. Pharmaceutical dosage forms and drug delivery systems. 5th ed. Philadelphia: Lea & Febiger; 1990:354–7.

  • 11.

    Stolar MH. Expiration dates of repackaged drug products. Am J Hosp Pharm. 1979; 36:170. Editorial.

  • 12.

    Remington's pharmaceutical sciences. 19th ed. Gennaro AR, ed. Easton, PA: Mack Publishing; 1990:1581–959.

Fluconazole Solution 1 mg/mL

in Extemporaneous Formulations
DOI:
https://doi.org/10.37573/9781585286522.230
Restricted access